Board reshuffle at Solid Biosciences (NASDAQ: SLDB) balances director classes
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Solid Biosciences Inc. reported a technical change to its Board structure. Effective at 4:00 p.m. Eastern Time on April 10, 2026, director Ilan Ganot resigned from the Class III director group and was immediately reappointed as a Class I director.
This adjustment sets both Class I and Class III at three directors each and is described as being for the sole purpose of achieving an equal balance among the Board’s three classes. Mr. Ganot’s new Class I term will run until the 2028 Annual Meeting of Stockholders.
The company plans to ask stockholders at the 2026 Annual Meeting to ratify, on an advisory basis, Mr. Ganot’s appointment as a Class I Director, reflecting its corporate governance focus. His compensation arrangements remain unchanged, and he will not receive any additional compensation for this reclassification.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Effective time of change: 4:00 p.m. Eastern Time
Board class sizes: Three Class I and three Class III directors
Advisory ratification meeting: 2026 Annual Meeting of Stockholders
+1 more
4 metrics
Effective time of change
4:00 p.m. Eastern Time
Time on April 10, 2026 when board reclassification became effective
Board class sizes
Three Class I and three Class III directors
Board adjusted class sizes to balance membership among three classes
Advisory ratification meeting
2026 Annual Meeting of Stockholders
Stockholders will be asked to ratify Ilan Ganot’s Class I appointment
New term end
2028 Annual Meeting of Stockholders
Expiration of Ilan Ganot’s term as Class I director
Key Terms
Emerging growth company, Class I Director, Annual Meeting of Stockholders, good corporate governance practices
4 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Class I Director regulatory
"the appointment of Mr. Ganot as a Class I Director"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
Annual Meeting of Stockholders regulatory
"at the Company’s 2028 Annual Meeting of Stockholders"
good corporate governance practices regulatory
"in keeping with the Company’s commitment to good corporate governance practices"
FAQ
What board change did Solid Biosciences (SLDB) disclose in this 8-K?
Solid Biosciences disclosed that director Ilan Ganot resigned from the Board as a Class III director and was immediately reappointed as a Class I director. The move is explicitly described as being for the sole purpose of balancing membership among the Board’s three director classes.
Why did Solid Biosciences (SLDB) move Ilan Ganot from Class III to Class I?
The company stated the change was made solely to achieve an equal balance of membership among the Board’s three classes. By shifting Ilan Ganot from Class III to Class I, both director classes now have three members, aligning the Board’s staggered structure more evenly.
How long will Ilan Ganot’s new term as a Class I director at SLDB last?
Following his reappointment as a Class I director, Ilan Ganot’s term will expire at Solid Biosciences’ 2028 Annual Meeting of Stockholders. Previously, as a Class III director, his seat would have been up for election at the company’s 2027 Annual Meeting of Stockholders.
Did Ilan Ganot receive any additional compensation for this board reclassification at SLDB?
The company reported no changes to Ilan Ganot’s compensation arrangements and no compensation due as a result of his resignation from the Board as a Class III director and his simultaneous appointment as a Class I Director. The change is portrayed as structural rather than financial.
How did Solid Biosciences (SLDB) alter the size of its Board classes?
Simultaneously with Ilan Ganot’s move, the Board reduced the number of Class III directors to three and increased the number of Class I directors to three. This realignment is designed to equalize membership among the three director classes without changing the overall Board size or role definitions.